首页> 外文期刊>Biomarkers in medicine >Long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1 correlates with microRNA-125b/microRNA-146a/microRNA-203 and predicts 2-year restenosis risk in coronary heart disease patients
【24h】

Long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1 correlates with microRNA-125b/microRNA-146a/microRNA-203 and predicts 2-year restenosis risk in coronary heart disease patients

机译:长的非编码RNA转移相关肺腺癌转录物1与MicroRNA-125B / microRNA-146A / microRNA-203相关,并预测冠心病患者的2年再狭窄风险

获取原文
获取原文并翻译 | 示例
       

摘要

Aim: To investigate correlations of long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1 (lnc-MALAT1) and its target microRNAs with clinical features and restenosis risk in coronary heart disease (CHD) patients post drug-eluting stent-percutaneous coronary intervention (DES-PCI). Materials & methods: A total of 274 CHD patients undergoing DES-PCI were enrolled, pre-operative plasma samples were obtained to detect lnc-MALAT1, miR-125b, miR-146a, miR-203 by RT-qPCR; 2-year restenosis was determined by quantitative coronary angiography. Results: Lnc-MALAT1 negatively correlated with miR-125b, miR-146a and miR-203 Furthermore, lnc-MALAT1, miR-125b, miR-146a and miR-203 correlated with diabetes mellitus, hyperuricemia, lesion properties, cholesterol, inflammation and cardiac function indexes. Additionally, lnc-MALAT1 was increased, while miR-125b and miR-146a were decreased in patients with 2-year restenosis than patients without 2-year restenosis; however, miR-203 did not differ. Conclusion: Lnc-MALAT1 and its target miRNAs might help manage restenosis risk in CHD patients post DES-PCI.
机译:目的:探讨长度非分量RNA转移相关肺腺癌转录腺癌转录1(LNC-MALAT1)及其靶心微小患者的相关性,冠心病(CHD)患者在药物洗脱支架 - 经皮冠状动脉介入后的临床特征和再狭窄风险(DES -pci)。材料和方法:纳入了274名CHD患者,纳入了DES-PCI,得到了预先进行的血浆样品以检测LNC-MALAT1,MIR-125B,MIR-146A,MIR-203通过RT-QPCR;通过定量冠状动脉血管造影确定2年的再狭窄。结果:LNC-MALAT1与MIR-125B,MIR-146A和MIR-203负相关,此外,LNC-MALAT1,MIR-125B,MIR-146A和MIR-203与糖尿病,高尿酸血症,病变性质,胆固醇,炎症和和心功能索引。此外,LNC-MALAT1增加,而MIR-125B和MIR-146A在2年再狭窄的患者中减少,而不是没有2年重新狭窄的患者;但是,MIR-203没有差异。结论:LNC-MALAT1及其目标MIRNA可能有助于DES-PCI后CHD患者的再狭窄风险。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号